Hikma Pharmaceuticals (LON:HIK) Insider Mazen Darwazah Acquires 14,000 Shares

Key Points

• Mazen Darwazah, an insider at Hikma Pharmaceuticals, purchased 14,000 shares at an average price of GBX 1,603, totaling £224,420 on September 16th.
• Research analysts have decreased their price targets for Hikma Pharmaceuticals, with JPMorgan lowering it from GBX 2,600 to GBX 2,500, while the stock retains an average rating of "Buy."
• The company has a market capitalization of £3.59 billion and a current ratio of 1.66, indicating a solid financial position.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Mazen Darwazah bought 14,000 shares of the company's stock in a transaction on Tuesday, September 16th. The stock was bought at an average price of GBX 1,603 per share, for a total transaction of £224,420.

Mazen Darwazah also recently made the following trade(s):

• On Thursday, August 7th, Mazen Darwazah bought 200,000 shares of Hikma Pharmaceuticals stock. The stock was bought at an average price of GBX 1,756 per share, for a total transaction of £3,512,000.

Hikma Pharmaceuticals Stock Performance

Shares of HIK traded down GBX 21 during mid-day trading on Friday, hitting GBX 1,615. The stock had a trading volume of 859,592 shares, compared to its average volume of 1,279,794. Hikma Pharmaceuticals PLC has a 52 week low of GBX 1,595 and a 52 week high of GBX 2,360. The business has a fifty day moving average price of GBX 1,825.85 and a 200-day moving average price of GBX 1,943.06. The firm has a market cap of £3.58 billion, a P/E ratio of 967.07, a PEG ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HIK shares. Jefferies Financial Group reissued a "buy" rating and issued a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. JPMorgan Chase & Co. lowered their price target on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating for the company in a report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of GBX 2,627.50.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.